Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Heart Lung Circ. 2016 Jan 19;25(5):425–434. doi: 10.1016/j.hlc.2016.01.002

Figure 3. Promising therapies targeting impaired cardiac contractility.

Figure 3

A schematic representing gene-based or small-molecule based therapies that manipulate SERCA2a activity by directly targeting SERCA2a or by SUMOylation. Cardiac myosin activators such as omecamtiv mecarbil targets contractile apparatus of the heart increasing the contracting of the left ventricle of the heart.